Aligos Therapeutics (NASDAQ:ALGS) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS

Aligos Therapeutics (NASDAQ:ALGS) released its earnings results on Friday. The company reported ($2.09) EPS for the quarter, topping analysts’ consensus estimates of ($2.28) by $0.19, FiscalAI reports. Aligos Therapeutics had a negative net margin of 241.01% and a negative return on equity of 160.72%. The business had revenue of $2.87 million for the quarter, compared to the consensus estimate of $4.85 million.

Aligos Therapeutics Stock Performance

ALGS traded down $0.44 during trading on Friday, reaching $4.07. The company had a trading volume of 101,665 shares, compared to its average volume of 130,776. The firm’s 50-day simple moving average is $5.37 and its 200 day simple moving average is $6.19. The company has a market cap of $25.42 million, a price-to-earnings ratio of -0.56 and a beta of 2.43. Aligos Therapeutics has a 12-month low of $3.98 and a 12-month high of $13.69.

Analyst Ratings Changes

ALGS has been the subject of a number of research reports. Weiss Ratings cut shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. HC Wainwright reaffirmed a “buy” rating on shares of Aligos Therapeutics in a report on Monday, August 10th. Finally, Jefferies Financial Group raised Aligos Therapeutics to a “strong-buy” rating in a report on Friday, September 25th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $38.50.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for viral infections and liver diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and selected respiratory viral infections.

Aligos’ pipeline has included investigational therapies such as ALG-000184, an oral capsid assembly modulator being developed for chronic HBV, and ALG-055009, an oral thyroid hormone receptor beta agonist under evaluation for MASH.